Pages
-
-
Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly
-
-
Treatment detection and movement disorder society-unified Parkinson's disease rating scale, part III estimation using finger tapping tasks
-
-
A Phase 1B trial in GBA1 Associated Parkinson's disease of BIA-28-6156, a glucocerebrosidase activator
-
-
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
-
-
First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator
-
-
Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery
-
-
A biomarker study in patients with GBA1-parkinson's disease and healthy controls
-
-
LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease
-
-
Fit for purpose of on-the-road driving and simulated driving
-
-
Smartphone and wearable sensors for the estimation of facioscapulohumeral muscular dystrophy disease severity
-
-
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
-
-
Mitochondrial function, grip strength, and activity are related to recovery of mobility after a total knee arthroplasty
-
-
Muscle velocity recovery cycles as pharmacodynamic biomarker
-
-
A Placebo-Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's Disease
-
-
A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects
-
-
Objective monitoring of facioscapulohumeral dystrophy during clinical trials using a smartphone app and wearables
-
-
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
-
-
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease
-
-
Acute retigabine-induced effects on myelinated motor axons in amyotrophic lateral sclerosis
-
-
Effects of mexiletine and lacosamide on nerve excitability in healthy subjects
-
-
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders
-
-
Modeling buprenorphine reduction of fentanyl-induced respiratory depression
-
-
A randomized first-in-human study with UB-312, a UBITh (R) alpha-synuclein peptide vaccine
-
-
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients
Pages